SOPHiA GENETICS Q2 Revenue Jumps 27%, Raises Full-Year Guidance
SOPH has more than doubled off its 52-week low of $2.92.
Summary
SOPHiA GENETICS posted Q2 2026 revenue of $23.3M, up 27% year-over-year, raised its full-year outlook, and unveiled new companion diagnostic agreements with AstraZeneca along with an MOU for an MSK joint venture. The rejection of Guardant Health's appeal removes a key litigation overhang.
Key Events · Earnings and Guidance · SOPH
-
Q2 Revenue Up 27%
Revenue reached $23.3M, driven by 60% U.S. volume growth and 70% liquid biopsy volume growth. Platform analysis volume grew 22% to 115,432.
-
Full-Year Guidance Raised
2026 revenue guidance raised to $94M-$96M (22%-24% growth) from $92M-$94M. Adjusted EBITDA loss guidance set at $29M-$32M, improving from $41.5M in FY2025.
-
AstraZeneca Companion Diagnostic Deals
Signed two multi-year companion diagnostic programs with AstraZeneca: a decentralized Solid Tumor CDx and a Hematological Oncology test.
-
MSK Joint Venture MOU
Signed MOU with Memorial Sloan Kettering Cancer Center to form a joint venture combining MSK's clinical expertise with SOPHiA's AI platform.
Analysis · SOPH · Technology
A strong second quarter saw revenue climb 27% to $23.3M, fueled by a 60% surge in U.S. volumes and a 70% jump in liquid biopsy volumes. Full-year revenue guidance was lifted to $94M–$96M, while the adjusted EBITDA loss narrowed 27% year-over-year. The balance sheet got a boost from a $57.5M public offering, pushing cash to $107.7M. Commercial momentum is accelerating, underscored by two new companion diagnostic programs with AstraZeneca and a memorandum of understanding with MSK for a joint venture. Meanwhile, the Guardant Health litigation overhang has cleared after the UPC Court of Appeal rejected Guardant's appeal and confirmed no injunction.
At the time of this filing, SOPH was trading at $6.00 on NASDAQ in the Technology sector, with a market capitalization of approximately $477.4M. The 52-week trading range was $2.92 to $6.77. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.